Literature DB >> 31132674

Case fatality rate and risk factors for Nipah virus encephalitis: A systematic review and meta-analysis.

Sebastien Kenmoe1, Maurice Demanou1, Jean Joel Bigna2, Cyprien Nde Kengne3, Abdou Fatawou Modiyinji4, Fredy Brice N Simo5, Sara Eyangoh6, Serge Alain Sadeuh-Mba1, Richard Njouom7.   

Abstract

BACKGROUND: A wide range of Nipah virus (NiV) encephalitis case fatality rates (CFR) have been reported. Data on the involvement of several potential risk factors in Nipah virus transmission remain controversial. We performed a systematic review and meta-analysis to estimate the pooled CFR of NiV encephalitis and to assess the risk factors for NiV infection.
METHODS: Articles published up to the 27thof November 2018 in MedLine, Embase and Web of knowledge databases were considered for this study. We included cross-sectional, cohort, and case-control studies that have reported NiV CFR and/or risk factors. Data were pooled with random-effects model. This review was registered in the PROSPERO, CRD42018116242.
FINDINGS: This global review included 22 citations (25 studies) including 2156, 1682, and 474 suspected, probable, and confirmed cases of NiV encephalitis, respectively. We determined a pooled CFR for NiV encephalitis at 61.0% (95% CI, 45.7-75.4; I² = 96.8%). Climbing trees (OR = 1.4; 95% CI; 1.0-1.9), male gender (OR = 1.5; 95% CI; 1.1-2.0), travel outside their own sub-district (OR = 2.0; 95% CI; 1.4-2.9), and exposure to date palm sap (DPS) (OR = 5.7; 95% CI; 3.8-8.6) or pigs (OR = 7.6; 95% CI; 1.2-45.4) were significantly associated with NiV infection.
CONCLUSION: Findings from this study suggest that NiV Encephalitis is associated with a high CFR and that male gender, travel outside their sub-district, climbing trees, and exposure to pigs and DPS are associated with an increased risk of NiV encephalitis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Case fatality rate; Encephalitis; Nipah virus; Risk factors

Mesh:

Year:  2019        PMID: 31132674     DOI: 10.1016/j.jcv.2019.05.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

Review 1.  Nipah virus, an emerging zoonotic disease causing fatal encephalitis.

Authors:  Ali M Alam
Journal:  Clin Med (Lond)       Date:  2022-06-27       Impact factor: 5.410

Review 2.  Bats in ecosystems and their Wide spectrum of viral infectious potential threats: SARS-CoV-2 and other emerging viruses.

Authors:  D Katterine Bonilla-Aldana; S Daniela Jimenez-Diaz; J Sebastian Arango-Duque; Mateo Aguirre-Florez; Graciela J Balbin-Ramon; Alberto Paniz-Mondolfi; Jose Antonio Suárez; Monica R Pachar; Luis A Perez-Garcia; Lourdes A Delgado-Noguera; Manuel Antonio Sierra; Fausto Muñoz-Lara; Lysien I Zambrano; Alfonso J Rodriguez-Morales
Journal:  Int J Infect Dis       Date:  2020-08-20       Impact factor: 3.623

3.  Detailed analysis of the pathologic hallmarks of Nipah virus (Malaysia) disease in the African green monkey infected by the intratracheal route.

Authors:  Curtis Cline; Todd M Bell; Paul Facemire; Xiankun Zeng; Thomas Briese; W Ian Lipkin; Joshua D Shamblin; Heather L Esham; Ginger C Donnelly; Joshua C Johnson; Lisa E Hensley; Anna N Honko; Sara C Johnston
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

4.  Sero-prevalence of Nipah antibodies among close contacts of the index case during 2019 Ernakulam outbreak.

Authors:  Reshmi Ramachandran; Merin S Jose; Rima R Sahay; Anita Shete
Journal:  J Family Med Prim Care       Date:  2022-06-30

5.  Headless Henipaviral Receptor Binding Glycoproteins Reveal Fusion Modulation by the Head/Stalk Interface and Post-receptor Binding Contributions of the Head Domain.

Authors:  Yao Yu Yeo; David W Buchholz; Amandine Gamble; Mason Jager; Hector C Aguilar
Journal:  J Virol       Date:  2021-07-21       Impact factor: 5.103

Review 6.  Utilization of Viral Vector Vaccines in Preparing for Future Pandemics.

Authors:  Kimberly A Hofmeyer; Katherine M Bianchi; Daniel N Wolfe
Journal:  Vaccines (Basel)       Date:  2022-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.